Target- |
Mechanism Immunostimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TLR agonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TLR agonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2015 |
Sponsor / Collaborator VaxInnate Corp. [+2] |
Start Date01 Nov 2014 |
Sponsor / Collaborator |
Start Date01 Mar 2014 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Hemagglutinin (HA)-based seasonal influenza vaccine(VaxInnate Corp.) ( TLR ) | Influenza A virus infection More | Discontinued |
VAX-102 ( TLR ) | Influenza A virus infection More | Discontinued |
VAX-128 ( hemagglutinin ) | Influenza A virus infection More | Discontinued |
VAX-161 ( TLR ) | Influenza A virus infection More | Discontinued |
Influenza vaccine monovalent (Vaxinnate) | Influenza, Human More | Discontinued |